Compare Nokia Corp (NOK) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Tango Therapeutics Inc. — how do they compare? Nokia Corp trades at $9.27 (market cap $54.48B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Nokia Corp is far larger — about 14.6× Tango Therapeutics Inc.'s market cap, and Nokia Corp pays a 1.74% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 65 Days and Tango Therapeutics Inc. for 0 Days on average.
| NOK | TNGX | |
|---|---|---|
Market Cap | $54.48B | $3.74B |
Volume | 85,996,980 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $16.83 | $32.90 |
52-Week Low | $5.55 | $7.50 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $52.50B | $2.76B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $9.86, down 0.4% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights partnerships in AI, satellite communications, and network automation, including an expanded collaboration with Microsoft announced on September 17, 2026.
The outlook is cautiously optimistic, supported by strong analyst buy ratings (59.6%) and a consensus price target of $17.50, implying significant upside. Key opportunities include growth in AI and cloud infrastructure demand, while risks involve competitive pressures and inconsistent earnings performance. Cash flow volatility remains a concern, with net cash flow negative in 2025 and 2026.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
